VRTX
Vertex Pharmaceuticals
NASDAQ: VRTX · Boston, MA · Healthcare
$477.36+4.27 (+0.90%)Closed
Market Cap$112.00B
Cash$13.80Bmost recent
Runwayprofitable
P/E (TTM)29.5EPS $14.72
52-Wk Range$366.54 – $529.59
Avg Volume1.5M3-month
Healthstrong
Commercial-stage biotech with a dominant cystic fibrosis franchise, expanding into pain, T1D, and sickle cell via Casgevy.
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$477.36-3.0%
Pipeline
Drug candidates sponsored by Vertex Pharmaceuticals · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | LUM/IVA | Cystic Fibrosis | Completed | 2020-10-09past | 4 | |
| Phase 4 | Suzetrigine | Acute Pain+1 more | Recruiting | 2027-01-30 | 4 | |
| Phase 3 | telaprevir | Hepatitis C+1 more | Completed | 2015-04past | 4 | |
| Phase 3 | VX-661/Ivacaftor | Cystic Fibrosis | Completed | 2017-02past | 1 | |
| Phase 3 | Tezacaftor/Ivacaftor | Cystic Fibrosis | Completed | 2018-08-09past | 1 | |
| Phase 3 | TEZ | Cystic Fibrosis | Completed | 2018-09past | 2 | |
| Phase 3 | VX-445/TEZ/IVA | Cystic Fibrosis | Completed | 2019-04-24past | 1 | |
| Phase 3 | VX-659/TEZ/IVA | Cystic Fibrosis | Terminated | 2020-09-09past | 1 | |
| Phase 3 | Ivacaftor | Cystic Fibrosis | Completed | 2020-10past | 12 | |
| Phase 3 | TEZ/IVA | Cystic Fibrosis | Completed | 2020-10-28past | 2 | |
| Phase 3 | LUM | Cystic Fibrosis | Completed | 2021-10-29past | 1 | |
| Phase 3 | VX-121/TEZ/D-IVA | Cystic Fibrosis | Completed | 2023-05-12past | 3 | |
| Phase 3 | Suzetrigine (SUZ) | Acute Pain | Completed | 2023-08-25past | 1 | |
| Phase 3 | IVA | Cystic Fibrosis | Completed | 2023-10-02past | 3 | |
| Phase 3 | ELX/TEZ/IVA | Cystic Fibrosis | Completed | 2026-01-29past | 8 | |
| Phase 3 | VX-880 | Diabetes Mellitus, Type 1+2 more | Recruiting | 2027-06-30 | 1 | |
| Phase 2 | CTX001 | Beta-Thalassemia+6 more | Active, not recruiting | 2027-11-14 | 3 | |
| Phase 3 | VNZ/TEZ/D-IVA | Cystic Fibrosis | Completed | 2029-07-30 | 2 | |
| Phase 2 | biricodar dicitrate | Lung Cancer | Terminated | 2001-02past | 1 | |
| Phase 2 | Ribavirin | Chronic Hepatitis C | Completed | 2008-05past | 1 | |
| Phase 2 | VX-809 | Cystic Fibrosis | Completed | 2011-05past | 3 | |
| Phase 2 | telaprevir or matching placebo | Hepatitis C+1 more | Completed | 2012-03past | 1 | |
| Phase 1 | VCH-222 or matching placebo | Hepatitis C | Completed | 2012-09past | 1 | |
| Phase 2 | VX-787 | Influenza Virus | Completed | 2012-10past | 1 | |
| Phase 2 | Lumacaftor | Cystic Fibrosis | Completed | 2014-04past | 1 | |
| Phase 2 | VX-135 | Chronic Hepatitis C+3 more | Completed | 2014-05past | 2 | |
| Phase 2 | VX-509 | Rheumatoid Arthritis | Completed | 2014-07past | 1 | |
| Phase 2 | VX-661 | Cystic Fibrosis | Completed | 2016-05-27past | 2 | |
| Phase 2 | VX-121 | Cystic Fibrosis | Completed | 2019-12-10past | 1 | |
| Phase 2 | VX-814 | Alpha 1-Antitrypsin Deficiency | Terminated | 2020-11-14past | 1 | |
| Phase 2 | VX-864 | Alpha1-Antitrypsin Deficiency | Completed | 2021-05-04past | 1 | |
| Phase 2 | VX-548 | Acute Pain+1 more | Completed | 2023-06-08past | 2 | |
| Phase 1 | VX-264 | Type 1 Diabetes | Active, not recruiting | 2027-03-12 | 1 | |
| Phase 2 | VX-993 | Acute Pain+2 more | Recruiting | 2027-03-25 | 4 | |
| Phase 2 | Povetacicept | Myasthenia Gravis, Generalized | Recruiting | 2029-03-02 | 1 | |
| Phase 1 | VCH-759 (BCH-27759) | Hepatitis C, Chronic | Completed | — | 1 | |
| Phase 1 | VCH 916 | HCV Infection | Completed | 2008-10past | 1 | |
| Phase 1 | VX-770 | Cystic Fibrosis | Completed | 2010-03past | 2 | |
| Phase 1 | Prednisone | Drug Interactions | Completed | 2013-08past | 1 | |
| Phase 1 | VX-440 | Cystic Fibrosis | Completed | 2016-09-14past | 1 | |
| Phase 1 | VX-840 | APOL1-mediated Kidney Disease | Completed | 2022-11-07past | 1 | |
| Phase 1 | VX-708 | Pain | Completed | 2023-03-07past | 1 | |
| Phase 1 | VX-634 | Alpha 1-Antitrypsin Deficiency | Completed | 2023-05-24past | 1 | |
| Phase 1 | Vanzacaftor | Cystic Fibrosis | Completed | 2023-06-14past | 1 | |
| Phase 1 | VX-147 | Focal Segmental Glomerulosclerosis (FSGS) | Completed | 2023-09-02past | 1 | |
| Phase 1 | IXP | Focal Segmental Glomerulosclerosis (FSGS) | Completed | 2024-12-20past | 1 | |
| Phase 1 | VX-150 | Pain | Completed | 2025-03-22past | 1 | |
| Phase 1 | VX-828 | Cystic Fibrosis | Active, not recruiting | 2026-07-16past | 1 | |
| Phase 1 | VX-581 | Cystic Fibrosis | Recruiting | 2026-11-19 | 1 | |
| Phase 1 | AVN-944 capsules for oral administration | Acute Leukemia+5 more | Completed | — | 1 | |
| N/A | Ivacaftor Exposed | Cystic Fibrosis | Completed | 2016-05past | 1 | |
| N/A | Unnamed | Cystic Fibrosis | Completed | 2019-12past | 1 | |
| N/A | Unnamed | Cystic Fibrosis | Completed | 2021-12-20past | 1 | |
| N/A | Unnamed | Cystic Fibrosis | Completed | 2025-11-27past | 1 | |
| N/A | Unnamed | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Active, not recruiting | 2026-12-31 | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
Large-cap biotech · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.